O

OrbiMed Portfolio holdings

AUM $5.4B Turnover 40.13%
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
Cap. Flow
-$312M
Cap. Flow %
-5.72%
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18
Avg Time Held Equity + Options
2.6 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
2.6 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.3 years

Top Buys

Rank Stock Value
1
AVBP icon
ArriVent BioPharma
AVBP
+$61.1M
2
CYTK icon
Cytokinetics
CYTK
+$52.8M
3
ESPR icon
Esperion Therapeutics
ESPR
+$33.3M
4
MRK icon
Merck
MRK
+$32.2M
5
QTTB icon
Q32 Bio
QTTB
+$31M

Top Sells

Rank Stock Value
1
RYZB icon
RayzeBio, Inc. Common Stock
RYZB
+$147M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$93.5M
3
UTHR icon
United Therapeutics
UTHR
+$84.9M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$71.7M
5
SWTX icon
SpringWorks Therapeutics
SWTX
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Miscellaneous 0.9%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RCM icon
126
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-4,803,200
Closed -$50.8M –
FUSN icon
127
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-3,122,770
Closed -$30M –
AMAM
128
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-296,000
Closed -$4.22M –
RYZB icon
129
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-2,365,213
Closed -$147M –
GRCL
130
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-9,308,726
Closed -$93.5M –
THRX
131
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-17,713,600
Closed -$71.7M –
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2024 Portfolio in Review

As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.

  • OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
  • OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
  • OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
  • OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
  • OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q1 2024.
  • OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.